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PREVENTION OF INFECTION BETWEEN IMMUNOCOMPROMISED
PATIENTS IN THE OUTPATIENT SETTING
King, R. The Children’s Hospital of Alabama, Birmingham, AL
Background/Objectives: The population of this outpatient unit
was pediatrics, aged 4 months to 22 years with moderate to severe
immunocompromise following bone marrow transplant. This unit
had open bed spaces, no visitor control, patients seen on first-
come, first-served basis, and the inpatient attending physician mak-
ing rounds on the patients when time permitted. Baseline data ob-
tained from IT revealed 48 readmissions from January 1 through
March 31, 2009. The objective of this project was a decrease in
readmissions due to infection, thereby improving patient outcomes.
Methods: A literature search as well as structured telephone inter-
views with other facilities with similar programs was conducted to
discover the best practice in outpatient settings. The information ob-
tained revealed the following changes in this unit’s process were in-
dicated: restructure of physical environment creating individual
patient rooms, limitation of visitors, computerized appointment
scheduling, and assignment of a physician dedicated to outpatients
only. Following planning sessions of the Medical Management
Team (MMT), a plan was developed. A business plan was submitted
to the Chief Financial Officer that included the cost of the construc-
tion of the individual patient rooms, a letter was sent to the parents
explaining the proposed changes along with rationales, and educa-
tion for the staff was carried out concerning the new process. The
new plan was put into place, and data was collected during January
1 through March 31, 2010, following the revisions.
Results: Following reconstruction of the open bay area into individ-
ual patient rooms, limiting visitors, implementing computerized ap-
pointment scheduling, and dedicating a physician to outpatients
only, this unit saw an 83% decrease in readmissions during the
time period of January – March 2010 as compared with January –
March 2009. Not only did the new process decrease admissions, it
also decreased morbidity, thereby improving patient outcomes.
Conclusions: The new isolation plan in this outpatient unit pro-
vided a significant decrease in the number of readmissions during
the time period studied. Due to this decrease, it is recommended
that similar units: provide individual patient rooms, limit the number
of visitors, implement computerized appointment scheduling, and
provide physician time dedicated to outpatients only in order to
improve patient outcomes.584
MANAGEMENT ON CENTRAL VENOUS ACCESS DEVICE: A RETROSPEC-
TIVE AUDIT
Vieira, S., Monroe, D. The Trustee of London Clinic, London, United
Kingdom
Introduction:Hickman line (HL) or other central venous access de-
vice (CVAD) insertion is essential prior to Bone marrow transplant
or high dose chemotherapy. Unfortunately is management of
CVAD’s is not without complications.
Method: A retrospective audit was carried out to evaluate CVAD
complications in 69 patients in 104 episodes. 31(45%) patients
were male and 32(46%) patients were female, 6 (9%) of them un-
known as information was lost to poor documentation and median
age 49 yrs (14-80).
Diagnosis: 14 (21%) Acute Leukaemia, 4 (6%) Chronic Leukae-
mia, 7 (10%) Multiple Myeloma, 6 (9%) Lymphoma, 3 (4%) Myelo
Displasic Syndrome, 28 (41) Solid Tumours 6 (9%) unknown.
Result: 62 patients with CVAD are 46 HL, 16 Groshong 4 Portha-
cath, 2 picc lines and was 1 neckline. There were 104 recorded com-
plications. 57 (55%) of these were treated as an inpatient and 47
(45%) as an outpatient. 70 (67%) febrile episodes were observed of
the 104 episodes. 16(15%) treated as an outpatient with oral antibi-
otics (AB), they were not neutropenic. 51 (49%) were treated as in
patient episodes and with intravenous AB. It is suggesting that pa-
tients should care for their own lines during their hospital stays.19S362(18%) of complications experiencedwas a blockedCVAD, only 4 ep-
isodes requiring urokinase. Others solved with flushing with Hepsal.
While patients are outside the hospital, the line should be flushed as
per local protocol. 11 (11%) of CVAD ended with line removal. Be-
cause of either infection or accidental removal by patient at
home.19% of blood cultures taken from the CVAD were sterile.
25 (23%) results were lost to poor documentation. 58% of blood
cultures were positive and microorganisms outlined in Table I.
Appropriate AB’s were given.
Table 1. Micro organism growth from the blood cultures
ORGANISM GROWTH Number %Gram + cocci 28 27
Gram - cocci 1 1
Gram – rods 21 21
Gram + rods 5 5
Fungal infection 2 2
Anaerobic spores 2 2
No Growth 20 19
Unknown 25 23
Total 104 100Conclusion: It is vital that patients receive training in the manage-
ment of their CVAD’s, regarding signs of infection, dressing and
flushing of their lines. During any neutropaenia, nursing staff remain
responsible for checking the CVAD’s, but care of the lines, unless in-
fected should continue to lie with the patient. As our audit shows
some hospitalization episodes are preventable with training or early
detection of infection.585
IS RITUXIMAB INFUSION GETTING EASIER? (IS IT SAFE TO GIVE RITUX-
IMAB FASTER?)
Vieira, S., Monroe, D. The Trustee of London Clinic, London, United
Kingdom
Introduction:Rituximab is a mono clonal antibody which causes ly-
sis of B lymphocytes, it is licen sed for the treatment of chemo ther-
apy resistant NHL often in com bination with chemo therapy.
Infusion related side effects are commonly reported, usually with
the first infusion.
Methods: A retrospective audit has been carried out of 16 patients, 7
female and 9 male. 13 were diagnosed DLBCL. Prior to the Ritux-
imab infusion 13 patients received premedication with Hydrocorti-
sone 100mg, Piriton 10 mg, Paracetamol 1 gm, three received
Dexametasone 12mg instead ofHydrocortisone on doctor’s instruc-
tion. During their first Rituximab infusion 4 patients experienced fe-
ver and chills and 1 had tumour pain. 2 patients were generally
unwell during the infusion, resulting in discontinuation of the Ritux-
imab. In 5 episodes, infusion rates had to be slowed, because of poor
tolerance. Second infusions were better tolerated without reducing
the infusion rate. Side effects have been listed below in table I.
Result: When Rituximab is infused for the first time, patients were
given all pre-medications as stated. When there was no incidence
of side effects reported the third infusion of Rituximab was given
at an increased rate as advised by the manufacturer. As indicated in
Table I there were no side effects reported such as fever, which
earlier occurred in 36% in the first infusion.
Conclusion:Rituximab is a monoclonal antibody, with the potential
of many side effects.When Rituximab is given for the first time, even
though a pre-medication was given, some side effects may still occur,
most commonly fever. Once the first infusion is completed,most side
effects resolved, third infusions can be given over a shorter period as
advised by manufacturer (as long as previous infusions are unevent-
ful).
Our audit has shown that when Rituximab is given uneventfully
twice, third and subsequent infusions can be given over a shorter
period with less pre-medication (as manufacturer advises).
